SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001346302-19-000033
Filing Date
2019-09-10
Accepted
2019-09-10 17:26:20
Documents
5
Period of Report
2019-09-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8-kdebtagreement.htm 8-K 48090
2 EXHIBIT 10.1 exhibit1018-kdebtagreement.htm EX-10.1 693759
3 EXHIBIT 99.1 exhibit991debtagreement.htm EX-99.1 31238
4 EXHIBIT 99.2 exhibit9928-kdebtagreement.htm EX-99.2 15205
5 xerislpharmrgba09.jpg GRAPHIC 74582
  Complete submission text file 0001346302-19-000033.txt   892248
Mailing Address 180 NORTH LASALLE STREET STE 1800 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET STE 1800 CHICAGO IL 60601 512-498-2670
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 191086242
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1